Alnylam Pharmaceuticals (ALNY) Projected to Post Earnings on Thursday

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 1st. Analysts expect Alnylam Pharmaceuticals to post earnings of ($0.55) per share and revenue of $584.32 million for the quarter. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, analysts expect Alnylam Pharmaceuticals to post $-2 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Alnylam Pharmaceuticals Stock Up 3.7 %

Shares of ALNY stock traded up $8.95 during trading hours on Friday, reaching $251.56. 835,531 shares of the company's stock were exchanged, compared to its average volume of 879,273. The stock has a market cap of $32.72 billion, a PE ratio of -115.93 and a beta of 0.30. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The stock's fifty day moving average price is $247.37 and its two-hundred day moving average price is $256.00. Alnylam Pharmaceuticals has a 1 year low of $143.50 and a 1 year high of $304.39.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CFO Jeffrey V. Poulton sold 967 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $246,749.39. Following the sale, the chief financial officer now owns 32,786 shares of the company's stock, valued at $8,366,003.62. The trade was a 2.86 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Yvonne Greenstreet sold 1,213 shares of the firm's stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $309,521.21. Following the completion of the transaction, the chief executive officer now directly owns 81,526 shares in the company, valued at approximately $20,802,989.42. This represents a 1.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 59,984 shares of company stock valued at $16,864,347 over the last ninety days. Insiders own 1.20% of the company's stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A hedge fund recently bought a new stake in Alnylam Pharmaceuticals stock. Brighton Jones LLC bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 1,032 shares of the biopharmaceutical company's stock, valued at approximately $243,000. Institutional investors and hedge funds own 92.97% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ALNY. Wells Fargo & Company raised their price target on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an "equal weight" rating in a report on Friday, March 21st. Scotiabank lifted their price target on Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a "sector outperform" rating in a research report on Monday, March 31st. Chardan Capital reissued a "buy" rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. HC Wainwright reaffirmed a "buy" rating and set a $500.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 2nd. Finally, JPMorgan Chase & Co. upgraded shares of Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and increased their price target for the stock from $280.00 to $328.00 in a report on Monday, March 24th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and twenty-two have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $315.58.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.